Los Angeles Capital Management & Equity Research Inc. Has $364,000 Position in Heron Therapeutics Inc (HRTX)

Los Angeles Capital Management & Equity Research Inc. reduced its stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 24.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,890 shares of the biotechnology company’s stock after selling 4,800 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Heron Therapeutics were worth $364,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in HRTX. Bank of New York Mellon Corp raised its holdings in shares of Heron Therapeutics by 4.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 313,312 shares of the biotechnology company’s stock valued at $9,916,000 after buying an additional 13,928 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Heron Therapeutics by 458.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,802 shares of the biotechnology company’s stock valued at $6,545,000 after buying an additional 169,738 shares during the period. Teachers Advisors LLC raised its holdings in shares of Heron Therapeutics by 3.4% during the 3rd quarter. Teachers Advisors LLC now owns 237,263 shares of the biotechnology company’s stock valued at $7,509,000 after buying an additional 7,724 shares during the period. Legal & General Group Plc raised its holdings in shares of Heron Therapeutics by 151.7% during the 3rd quarter. Legal & General Group Plc now owns 25,885 shares of the biotechnology company’s stock valued at $819,000 after buying an additional 15,599 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Heron Therapeutics by 36.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock valued at $196,016,000 after buying an additional 1,661,318 shares during the period.

HRTX stock opened at $17.50 on Tuesday. Heron Therapeutics Inc has a 52-week low of $16.20 and a 52-week high of $42.90. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -7.17 and a beta of 1.45.



Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.30). Heron Therapeutics had a negative return on equity of 47.05% and a negative net margin of 194.43%. The business had revenue of $31.60 million for the quarter, compared to analysts’ expectations of $28.04 million. During the same quarter in the prior year, the firm earned ($1.09) earnings per share. Heron Therapeutics’s revenue for the quarter was up 172.4% compared to the same quarter last year. As a group, equities analysts anticipate that Heron Therapeutics Inc will post -1.78 earnings per share for the current fiscal year.

HRTX has been the topic of several analyst reports. Cantor Fitzgerald downgraded Heron Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, March 4th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Northland Securities set a $55.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Stifel Nicolaus restated a “buy” rating and set a $54.00 price objective on shares of Heron Therapeutics in a report on Friday, February 22nd. Finally, Needham & Company LLC restated a “buy” rating and set a $64.00 price objective (down from $66.00) on shares of Heron Therapeutics in a report on Wednesday, January 16th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Hold” and an average price target of $51.20.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/05/14/los-angeles-capital-management-equity-research-inc-has-364000-position-in-heron-therapeutics-inc-hrtx.html.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.